期刊文献+

Role of Hormonal Manipulation in Prostate Cancer Management

下载PDF
导出
摘要 Prostate cancer(PCa)treatment has seen several important developments over the last few decades in the form of improved surgical methods and advanced radiotherapy techniques but androgen deprivation therapy(ADT)still remains the cornerstone of medical management of this common male malignancy.The discovery of androgen-dependent nature of PCa about three-quarters of a century ago was a turning point that has since led to the development of various pharmacological agents which rely on the basic principle of hormonal manipulation in the form of ADT to alter disease progression.Initially employed for metastatic disease only,ADT for PCa in the current clinical practice finds use multiple stages of the disease.The present review summarises the chronological evolution of agents used for hormonal manipulation in the management of PCa,highlighting the pros and cons of each and sheds light on the potential future advances in this area.
出处 《Proceedings of Anticancer Research》 2018年第1期45-53,共9页 抗癌研究
  • 相关文献

参考文献1

二级参考文献77

  • 1Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29: 2040-5.
  • 2Bolla M, van Poppel H, Tombal B. 10-year results of adjuvant radiotherapy after radical prostatectomy in pT3NO prostate cancer (EORTC 22991) (abstract). Int J Radiat Biol Phys 2010; 78: s29.
  • 3Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G etal. Adjuvant radiotherapy for pathological T3NOMO prostate cancer significantly reduces risk of metastases and improves survivah Iong-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62.
  • 4Whittington R, Broderick GA, Arger P, Malkowicz SB, Epperson RD et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44:1107-10.
  • 5Zelefsky M J, Leibel SA, Burman CM, Kutcher G J, Harrison A et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755-61.
  • 6D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A etal. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with crinicarly localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-7.
  • 7Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP etal. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-18.
  • 8Lawton CA, DeSilvio M, Roach M 3rd, U hl V, Kitsch R etal. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646--55.
  • 9Crook J, Ludgate C, Malone S, Lim J, Perry Get al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant a ndrogen deprivation before standard-dose radiotherapy for clinicatly localized prostate cancer.Int J Radiat Oncol Biol Phys 2004; 60: 15-23.
  • 10Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部